| 76.27 -0.21 (-0.27%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 92.33 | 1-year : | 95.26 |
| Resists | First : | 79.05 | Second : | 81.56 |
| Pivot price | 78.64 |
|||
| Supports | First : | 75 | Second : | 62.4 |
| MAs | MA(5) : | 77.25 |
MA(20) : | 78.72 |
| MA(100) : | 63.22  |
MA(250) : | 50.55 |
|
| MACD | MACD : | 1 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 25.8 |
D(3) : | 29.8 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 82.94 | Low : | 35.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KNSA ] has closed above bottom band by 2.4%. Bollinger Bands are 62.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 78.74 - 79.19 | 79.19 - 79.67 |
| Low: | 74.9 - 75.39 | 75.39 - 75.92 |
| Close: | 75.35 - 76.2 | 76.2 - 77.12 |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Fri, 11 Sep 2026
Squarepoint Ops LLC Has $8.96 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Wed, 09 Sep 2026
KNSA: Record Q2 revenue and pipeline progress highlight strong growth and future potential - tradingview.com
Fri, 04 Sep 2026
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Fall 3.2% -- What GF Score of 46 Tells Investors - GuruFocus
Fri, 04 Sep 2026
Kiniksa sets a live healthcare talk for Sept. 9 - stocktitan.net
Fri, 04 Sep 2026
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference - finance.yahoo.com
Thu, 03 Sep 2026
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 48 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 100.9 (%) |
| Shares Short | 4,280 (K) |
| Shares Short P.Month | 4,510 (K) |
| EPS | 0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.39 |
| Profit Margin | 9.5 % |
| Operating Margin | 11.1 % |
| Return on Assets (ttm) | 8 % |
| Return on Equity (ttm) | 14 % |
| Qtrly Rev. Growth | 55.4 % |
| Gross Profit (p.s.) | 9.49 |
| Sales Per Share | 17.41 |
| EBITDA (p.s.) | 2.11 |
| Qtrly Earnings Growth | 30.3 % |
| Operating Cash Flow | 185 (M) |
| Levered Free Cash Flow | 126 (M) |
| PE Ratio | 77.04 |
| PEG Ratio | 0 |
| Price to Book value | 9.09 |
| Price to Sales | 4.38 |
| Price to Cash Flow | 19.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|